IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

New Horizon Health IPO: Valuation Insights

New Horizon Health IPO Initiation: Screening for Cancer

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a> is a leading player in China’s colorectal cancer screening market. It has two self-developed cancer screening tests, Pupu Tube, and ColoClear, the core component of which, ColoClear IVD, is approved by the NMPA. New Horizon is set to launch a $300 million Hong Kong IPO on Thursday, according to press reports.</p><p>In <a href="https://www.smartkarma.com/insights/new-horizon-health-ipo-initiation-screening-for-cancer" target="_blank" data-smartkarma-citation="insights:46909" rel="noopener">New Horizon Health IPO Initiation: Screening for Cancer</a>, we stated that New Horizon is a play on the rapid growth of the cancer screening market in China, particularly the colorectal cancer screening market. We concluded that that New Horizon has the right ingredients to capitalise on this market opportunity. </p><div class="content-highlight"><p>In this note, we look at the PHIP which disclose the 9M20 results and the all-important NMPA approval for ColoClear IVD. The NMPA issued the registration certificate for ColoClear IVD in November 2020 which will open multiple growth opportunities. Overall, we continue to believe that New Horizon is worth a closer look and has attractive fundamentals. </p></div>

New Horizon Health (NHH HK) is a leading player in China’s colorectal cancer screening market. It has two self-developed cancer screening tests, Pupu Tube, and ColoClear, the core component of which, ColoClear IVD, is approved by the NMPA. New Horizon is set to launch a $300 million Hong Kong IPO on Thursday, according to press reports.In New Horizon Health IPO Initiation: Screening for Cancer, we stated that New Horizon is a play on the rapid growth of the cancer screening market in China, particularly the colorectal cancer screening market. We concluded that that New Horizon has the right ingredients to capitalise on this market opportunity. In this note, we look at the PHIP which disclose the 9M20 results and the all-important NMPA approval for ColoClear IVD. The NMPA issued the registration certificate for ColoClear IVD in November 2020 which will open multiple growth opportunities. Overall, we continue to believe that New Horizon is worth a closer look and has attractive fundamentals. 

New Horizon Health IPO: Poised for Growth